GlassScriptPhysician profile
Kim R Emmett
NPI 1437174356
$1,976.93
in general payments reported to CMS, 2019-2025
31 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $169 · 2021: $30.14 · 2022: $186 · 2023: $203 · 2024: $278 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.94 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $360.91 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $195.55 | 2019-2024 | |
| Novo Nordisk INC | $148.03 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $128.38 | 2019-2022 | |
| Lilly USA, LLC | $109.73 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $95.70 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $93.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $88.45 | 2019-2025 | Shingrix, Arexvy |
| Amgen INC. | $77.94 | 2019-2022 | |
| Astellas Pharma US INC | $76.11 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.77 | 2019-2025 | Jardiance, Ofev |
| Theratechnologies INC. | $57.31 | 2022-2025 | Trogarzo, Egrifta |
| Xeris Pharmaceuticals, INC. | $53.81 | 2021-2025 | Gvoke Hypopen |
| Abbott Laboratories | $49.11 | 2019-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $44.49 | 2022-2025 | Eliquis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35.64 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $35.21 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $31.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.95 | 2023 | Xifaxan |
| Kyowa Kirin, INC. | $25.01 | 2023 | Crysvita |
| Dexcom, INC. | $20.11 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $17.22 | 2019 | |
| Dynavax Technologies Corporation | $17.07 | 2025 | Heplisav-B |
| Hikma Pharmaceuticals USA | $16.72 | 2019 | |
| Sumitomo Pharma America, INC. | $15.33 | 2024 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $15.28 | 2024 | Strensiq |
| Nalpropion Pharmaceuticals LLC | $14.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.40 | 2019 | |
| Daiichi Sankyo INC. | $12.71 | 2019 | |
| Allergan, INC. | $12.39 | 2019 | |
| Gilead Sciences, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Emmett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.